Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TYR | P14679 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.35 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylated Hydroxytoluene SCHEMBL4826096 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL4820691 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL864243 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL7738522 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL6908300 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL23090058 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL20455508 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL6901302 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL17835978 | 0.92 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL6039994 | 0.90 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2TYRCA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640277-A2 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR USE IN THERAPY | Sage Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250319106-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-3699175-B1 | FUNCTIONALIZED ALIPHATIC POLYESTERS AND PROCESS FOR PRODUCING THE SAME | KEMIJSKI INST (SI) | 2022-05-04 | — | — | EP | claimed |
| EP-3781551-A1 | D-GLUCARO-6,3-LACTONE MONOESTER AND A PROCESS FOR THE PREPARATION THEREOF | BASF SE (DE) | 2021-02-24 | — | — | EP | claimed |
| EP-3699175-A1 | FUNCTIONALIZED ALIPHATIC POLYESTERS AND PROCESS FOR PRODUCING THE SAME | Kemijski Institut (SI) | 2020-08-26 | — | — | EP | claimed |
| WO-2019201718-A1 | D-GLUCARO-6,3-LACTONE MONOESTER AND A PROCESS FOR THE PREPARATION THEREOF | BASF SE (DE) | 2019-10-24 | — | — | WO | claimed |
| US-20070043134-A1 | Polymerisation initiators | IC INNOVATIONS LTD. (GB) | 2007-02-22 | — | — | US | claimed |
| WO-2004081083-A1 | POLYMERISATION INITIATORS | IC INNOVATIONS LTD (GB) | 2004-09-23 | — | — | WO | claimed |
| WO-2004018487-A1 | CHIRAL ORGANOSILICON HYDRIDES | CHIROGEN PTY LIMITED (AU) | 2004-03-04 | — | — | WO | claimed |
| WO-2004011473-A1 | ORGANOGERMANIUM COMPOUNDS AND METHODS FOR THEIR USE | CHIROGEN PTY LIMITED (AU) | 2004-02-05 | — | — | WO | claimed |
| US-20260125416-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260098053-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4321519-B1 | NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS | SAGE THERAPEUTICS LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3728285-B1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4161908-B1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | ANNJI PHARM CO LTD (TW) | 2026-04-01 | — | — | EP | disclosed |
| JP-2000086755-A | CATALYST COMPOSITION FOR POLYMERIZING PROPYLENE OXIDE | JAPAN CHEMICAL INNOVATION INSTITUTE | 2000-03-28 | — | — | JP | disclosed |
| EP-0984016-A1 | ALUMINUM COMPOUND AND PROCESS FOR PRODUCING THE SAME, CATALYST FOR OLEFIN POLYMER PRODUCTION, AND PROCESS FOR PRODUCING OLEFIN POLYMER | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2000-03-08 | — | — | EP | disclosed |
| WO-2000000525-A1 | A LIVING POLYMERISATION PROCESS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 2000-01-06 | — | — | WO | disclosed |
| US-5929181-A | Method for preparation of copolymers of ethylene/norbornene-type monomers with nickel catalysts | THE B.F.GOODRICH CO. (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1998056837-A1 | METHOD FOR THE PREPARATION OF COPOLYMERS OF ETHYLENE/NORBORNENE-TYPE MONOMERS WITH NICKEL CATALYSTS | THE B.F. GOODRICH COMPANY (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319106-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | NR3C2, NR3C1, CYP11B1 | ALDH1A1 650/4885SMN1; SMN2 925/4885TYR 4204/4885 |
| US-20260098053-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, GRIN2C, GRIN2D | ALDH1A1 1395/4885SMN1; SMN2 114/4885TYR 2158/4885 |
| US-20260125416-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | HSD3B1, HSD3B2, HSD11B1 | ALDH1A1 451/4885SMN1; SMN2 2625/4885TYR 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.